Hwaseong-si, South Korea

Mijung Lee


 

Average Co-Inventor Count = 8.7

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Mijung Lee - Pioneering Thiazole Derivatives and SHP2 Inhibitors

Introduction

Mijung Lee, an innovative inventor based in Hwaseong-si, South Korea, has made significant contributions to the field of pharmaceuticals. With a total of two patents to his name, his work focuses primarily on developing novel compounds that address critical health challenges.

Latest Patents

One of Mijung Lee's notable patents is for Thiazole Derivatives and Pharmaceutically Acceptable Salts Thereof. This invention provides a unique thiazole derivative along with a method for its preparation. The derivative has selective inhibitory activity against cyclin-dependent kinase (CDK), presenting potential applications as a preventive or therapeutic agent for various diseases associated with CDK.

Additionally, Lee has developed a patent titled SHP2 Inhibitor and Use Thereof. This invention relates to an inhibitor for SHP2, and includes a pharmaceutical composition aimed at preventing or treating diseases associated with SHP2. The implications of this research are substantial, making strides in effectively preventing or treating diseases connected with this target.

Career Highlights

Throughout his career, Mijung Lee has worked with notable companies such as Kanaph Therapeutics Inc. and Yungjin Pharm Co., Ltd. These experiences have helped him to refine his work and contribute to vital research in the pharmaceutical sector.

Collaborations

Collaboration has been a key element in Mijung Lee's journey as an inventor. He has had the opportunity to work alongside esteemed colleagues such as Jieun Min and Kangwoo Lee. Their teamwork in research projects has undoubtedly fueled innovation and progress in their field.

Conclusion

Mijung Lee stands out as a vital contributor to the pharmaceutical industry with his innovative inventions that target critical health issues. His latest patents in thiazole derivatives and SHP2 inhibitors illustrate his dedication to advancing medicine and technology. As he continues to push the boundaries of research and development, the impact of his work is expected to be felt in the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…